A Modular Phase I, Open-label Study to Assess the Safety, Pharmacokinetics, and Drug Interaction Potential and Relative Bioavailability of Saruparib in Patients With Advanced Solid Malignancies
Latest Information Update: 30 Apr 2025
At a glance
- Drugs Saruparib (Primary) ; Digoxin; Furosemide; Metformin; Rabeprazole; Rosuvastatin
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 25 Apr 2025 Status changed from not yet recruiting to recruiting.
- 01 Apr 2025 New trial record